NeoGenomics Collaborates with Inivata to Commercialize InVisionFirst-Lung Liquid Biopsy Test in the US
Shots:
- NeoGenomics will invest $25M in Inivata- with an option to buy the entire company. The amount will be paid in two tranches of $12.5M with the company will get a seat on the Inivata Board of Directors
- Additionally- NeoGenomics and Inivata will get collaborate with biopharmaceutical companies around Inivata's liquid biopsy platform drawing on both companies' technology and expertise
- InVisionFirst-Lung is a ctDNA NGS liquid biopsy assay testing 37 genes and covers NCCN guideline-recommended genomic drivers with FDA-approved targeted therapies for NSCLC. Inivata has developed oncology test platform- including both InVisionFirst-Lung and RaDaR test- the newly launched personalized assay for the detection of residual disease and recurrence
Click here to read full press release/ article | Ref: Business wire | Image: StraitTimes
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
